取卵后阴道内暴露于精浆不会提高体外受精或卵胞浆内单精子注射治疗后的活产率:一项双盲、安慰剂对照随机试验
这项双盲、安慰剂对照随机试验纳入792对接受体外受精(IVF)治疗的夫妇,取卵日随机给予阴道内放置配偶精浆或生理盐水。精浆组活产率为26.5%,对照组为29.8%(相对风险RR 0.86,95%置信区间CI 0.70-1.07),两组无统计学显著差异。结论认为取卵后阴道内使用精浆未提高活产率或临床妊娠率。
要点
- 取卵后阴道内放置精浆未提高IVF活产率(精浆组26.5% vs 对照组29.8%,RR 0.86,95%CI 0.70-1.07)。
- 精浆组临床妊娠率28.8%,对照组33.6%(RR 1.00,95%CI 0.97-1.03),无统计学显著差异。
- 精浆组尿妊娠试验阳性率35.4%,对照组37.3%(RR 0.93,95%CI 0.78-1.10),无统计学显著差异。
核心结论
- 取卵后立即阴道内使用配偶精浆未提高活产率或临床妊娠率。
- 作者认为免疫因素对胚胎着床的重要性不受质疑,但取卵后引入配偶精浆未能改善IVF治疗的活产率。
研究设计与样本
- 双盲、安慰剂对照前瞻性研究,在揭盲干预类型前进行结局评估,按意向性治疗(ITT)方案分析。
- 共纳入792对计划接受IVF治疗周期的夫妇,精浆组393对,对照组399对,在单中心机构历时5年招募。
- 取卵日将夫妇随机分组,分别接受阴道内放置配偶精浆或生理盐水,参与者和医生均对分组设盲。
主要发现
- 精浆组尿妊娠试验阳性率为35.4%(RR 0.93,95%CI 0.78-1.10),对照组为37.3%。
- 精浆组临床妊娠率为28.8%(RR 1.00,95%CI 0.97-1.03),对照组为33.6%。
- 精浆组活产率为26.5%(RR 0.86,95%CI 0.70-1.07,校正移植日、女性年龄和受精卵母细胞数),对照组为29.8%。
- 两组各项结局均无统计学显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To detect whether intravaginal exposure to prepared seminal plasma led to an absolute increase in live birth rate (LBR) after in vitro fertilization (IVF) by 10% compared with placebo. It has been suggested that intravaginal deposition of seminal plasma after ovum pick-up (OPU) for IVF treatment, increases pregnancy and LBRs. DESIGN: Double-blind, placebo-controlled prospective study. An outcome assessment was made before the type of intervention was unblinded. The outcome data were analyzed according to an intention-to-treat protocol. SETTING: University Hospital. PATIENTS: Couples scheduled for an IVF treatment cycle: in total, 792 couples (393 in the seminal plasma group and 399 in the control group) were recruited over a 5-year period of inclusion in a single-center setting. INTERVENTION: On the day of OPU, the couples were randomized into groups receiving either vaginal deposition of prepared seminal plasma from the partner or saline. Both participants and the physician were blind to the grouping. MAIN OUTCOME MEASURES: The primary outcome was a live birth (LB). The secondary outcomes were a positive pregnancy test, defined as human chorionic gonadotropin identified in urine 3 weeks after OPU , and clinical pregnancy, defined as an intrauterine viable pregnancy assessed using transvaginal sonography after 5-7 weeks. RESULTS: In the index group, 35.4% had a positive pregnancy test (relative risk [RR],0.93; 95% confidence interval {CI} 0.78-1.10), 28.8% had a clinical pregnancy (RR 1.00, 95% CI 0.97-1.03), and 26.5% had a LB (RR 0.86; 95% CI 0.70-1.07), adjusted for day of transfer, female age, and number of fertilized oocytes. Corresponding rates in the control group were 37.3%, 33.6%, and 29.8%. No statistically significant differences regarding outcomes between the two intervention groups were found. CONCLUSION: Prepared seminal plasma applied in the vagina directly after OPU did not increase the rates of LB or clinical pregnancies. The importance of immunological factors to allow the implantation of an embryo is not questioned, but no improvement in the LBRs in IVF treatment by introducing the male partner's prepared seminal plasma after OPU could be found. CLINICAL TRIAL REGISTRATION NUMBER: Clinicaltrials.gov, ID NCT02716753. Registration date 17 March, 2016, first enrollment November, 2016, completed March, 2023.
引用
- Liffner S, Bladh M, Rodriguez-Martinez H, et al. Intravaginal exposure to seminal plasma after ovum pick-up does not increase live birth rates after in vitro fertilization or intracytoplasmic sperm injection treatment: a double-blind, placebo-controlled randomized trial. Fertil Steril. 2024. PMID: 38342372. doi:10.1016/j.fertnstert.2024.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。